<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04602871</url>
  </required_header>
  <id_info>
    <org_study_id>Cov-2-2020</org_study_id>
    <nct_id>NCT04602871</nct_id>
  </id_info>
  <brief_title>Early Detection of COVID-19 Using Breath Analysis - Feasibility Study</brief_title>
  <acronym>COVID-19</acronym>
  <official_title>Early Detection of the 2019 Novel Coronavirus (SARS-CoV-2) Using Breath Analysis - Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scentech Medical Technologies Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scentech Medical Technologies Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early Detection of COVID-19 Using Breath Analysis -Feasibility Study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An interventional diagnostic prospective study study with risks and minimal constraints.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 3, 2020</start_date>
  <completion_date type="Anticipated">January 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between Volatile Organic Compounds pattern in-breath biopsy and COVID-19 detection.</measure>
    <time_frame>Through the study completion, up to 3 months.</time_frame>
    <description>Correlation between Volatile Organic Compounds found in breath biopsy chromatography and COVID-19 detection in a swab test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between Volatile Organic Compounds pattern and the course of the disease</measure>
    <time_frame>Through the study completion, up to 3 months.</time_frame>
    <description>Correlation between Volatile Organic Compounds found in breath biopsy chromatography and COVID-19 detection intensity in a swab test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>COVID 19 Positive patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with COVID-19, qPCR for SARS-CoV-2 confirmed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>COVID-19 Negative subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Breath Biopsy</intervention_name>
    <description>Breath Biopsy sampling using the ReCIVAÂ® Breath Sampler</description>
    <arm_group_label>COVID 19 Positive patients</arm_group_label>
    <arm_group_label>Healthy subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Hospitalized group:&#xD;
&#xD;
          -  Age 18 to 75 years at the time of consent&#xD;
&#xD;
          -  Positive results for SARS-CoV-2&#xD;
&#xD;
          -  Capable of understanding written and/or spoken language&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Was not treated with Anti-viral drugs&#xD;
&#xD;
          -  Not a pregnant woman&#xD;
&#xD;
        Healthy group:&#xD;
&#xD;
          -  Healthy volunteers&#xD;
&#xD;
          -  Age 18 to 75 years at the time of consent&#xD;
&#xD;
          -  No history of COVID-19&#xD;
&#xD;
          -  Capable of understanding written and/or spoken language&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Was not treated with Anti-viral drugs&#xD;
&#xD;
          -  Not a pregnant woman&#xD;
&#xD;
        Sexes Eligible for Study: All&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Hospitalized group:&#xD;
&#xD;
          -  Age under 18 years old&#xD;
&#xD;
          -  (Anticipated) inability to complete breath sampling procedure due to e.g. hyper- or&#xD;
             hypoventilation, respiratory failure or claustrophobia when wearing the sampling mask&#xD;
&#xD;
          -  Persons under guardianship or deprived of liberty&#xD;
&#xD;
          -  Patients with the following diseases: Cancer, Asthma, Chronic Respiratory Disease&#xD;
&#xD;
        Healthy group:&#xD;
&#xD;
          -  Age under 18 years old&#xD;
&#xD;
          -  History of COVID-19&#xD;
&#xD;
          -  Persons under guardianship or deprived of liberty&#xD;
&#xD;
          -  Subjects with the following diseases: Cancer, Asthma, Chronic Respiratory Disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Shitrit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Meir Medical Center, Kfar Saba, Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Natalie Dror, PhD</last_name>
    <phone>+972-528-264282</phone>
    <email>natalie@scentech-medical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Be'er Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Novac, MD</last_name>
      <phone>+972544782226</phone>
      <email>victorno@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Victor Novac, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 21, 2020</study_first_submitted>
  <study_first_submitted_qc>October 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2020</study_first_posted>
  <last_update_submitted>October 23, 2020</last_update_submitted>
  <last_update_submitted_qc>October 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPDs are to be shared with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

